Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. - Arnulf B; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; van de Velde H; Feng H; Cakana A; Deraedt W; Moreau P (Haematologica, 2012)